DE69626393D1 - Spezifische oligonukleotide für hepatitis b virus - Google Patents
Spezifische oligonukleotide für hepatitis b virusInfo
- Publication number
- DE69626393D1 DE69626393D1 DE69626393T DE69626393T DE69626393D1 DE 69626393 D1 DE69626393 D1 DE 69626393D1 DE 69626393 T DE69626393 T DE 69626393T DE 69626393 T DE69626393 T DE 69626393T DE 69626393 D1 DE69626393 D1 DE 69626393D1
- Authority
- DE
- Germany
- Prior art keywords
- oligonucleotids
- hepatitis
- virus
- specific
- hbv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000700721 Hepatitis B virus Species 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/313—Phosphorodithioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46739795A | 1995-06-06 | 1995-06-06 | |
| PCT/EP1996/002432 WO1996039502A1 (en) | 1995-06-06 | 1996-06-04 | Oligonucleotides specific for hepatitis b virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69626393D1 true DE69626393D1 (de) | 2003-04-03 |
| DE69626393T2 DE69626393T2 (de) | 2003-12-04 |
Family
ID=23855522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69626393T Expired - Lifetime DE69626393T2 (de) | 1995-06-06 | 1996-06-04 | Spezifische oligonukleotide für hepatitis b virus |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US5856459A (de) |
| EP (1) | EP0832211B1 (de) |
| AT (1) | ATE233318T1 (de) |
| AU (1) | AU6125296A (de) |
| CA (1) | CA2226458A1 (de) |
| DE (1) | DE69626393T2 (de) |
| DK (1) | DK0832211T3 (de) |
| ES (1) | ES2188760T3 (de) |
| WO (1) | WO1996039502A1 (de) |
| ZA (1) | ZA964445B (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040054156A1 (en) * | 1992-05-14 | 2004-03-18 | Kenneth Draper | Method and reagent for inhibiting hepatitis B viral replication |
| US5646262A (en) | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
| US5985662A (en) * | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
| ES2207753T3 (es) | 1996-10-31 | 2004-06-01 | Biogen, Inc. | Nuevos inhibidores de la hepatitis b. |
| CN1057302C (zh) * | 1997-08-27 | 2000-10-11 | 中国科学院上海生物化学研究所 | 抑制乙型肝炎病毒复制的反义脱氧寡核苷酸 |
| CN1215058A (zh) * | 1997-10-21 | 1999-04-28 | 中国科学院上海生物化学研究所 | 新的三链形成寡核苷酸结构及其在抗乙肝病毒中的应用 |
| KR100715954B1 (ko) | 1998-12-04 | 2007-05-09 | 바이오겐 아이덱 엠에이 인코포레이티드 | 펩티드 리간드에 의하여 부착된 다중 면역원성 성분을보유한 ｈｂｖ 코어 항원 입자 |
| AU2001254670A1 (en) * | 2000-03-02 | 2001-09-12 | Akzo Nobel N.V. | Detection of hepatitis b virus rna |
| US6583279B1 (en) | 2001-01-26 | 2003-06-24 | Becton, Dickinson And Company | Sequences and methods for detection of hepatitis B virus |
| EP1383782A1 (de) * | 2001-03-26 | 2004-01-28 | Sirna Therpeutics, Inc. | Oligonukleotidvermittelte inhibierung der replikation des hepatitis--b-virus und des hepatitis-c-virus |
| US6881831B2 (en) * | 2001-05-16 | 2005-04-19 | Migenix Inc. | Nucleic acid-based compounds and methods of use thereof |
| US20030140362A1 (en) * | 2001-06-08 | 2003-07-24 | Dennis Macejak | In vivo models for screening inhibitors of hepatitis B virus |
| AU2003253651C1 (en) | 2002-06-14 | 2010-06-03 | Gen-Probe Incorporated | Compositions and methods for detecting hepatitis B virus |
| EP1403385A1 (de) * | 2002-09-27 | 2004-03-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methode zur Darstellung der Replikation von HBV und zum Testen der Sensibilität von Wirkstoffen |
| CA2503693A1 (en) * | 2002-10-29 | 2004-05-13 | Coley Pharmaceutical Group, Ltd. | Use of cpg oligonucleotides in the treatment of hepatitis c virus infection |
| EP2512491B1 (de) | 2009-10-16 | 2017-10-11 | Glaxo Group Limited | Hbv-antisense-hemmer |
| US8642752B2 (en) * | 2011-04-21 | 2014-02-04 | Isis Pharmaceuticals, Inc. | Modulation of Hepatitis B virus (HBV) expression |
| JP6165723B2 (ja) * | 2011-06-30 | 2017-07-19 | アローヘッド ファーマシューティカルズ インコーポレイテッド | Ｂ型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法 |
| GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
| KR20180038465A (ko) | 2015-08-07 | 2018-04-16 | 애로우헤드 파마슈티컬스 인코포레이티드 | Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법 |
| JOP20190015A1 (ar) | 2016-08-04 | 2019-02-04 | Arrowhead Pharmaceuticals Inc | عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب |
| KR102273071B1 (ko) * | 2018-06-12 | 2021-07-05 | 주식회사 에이엠사이언스 | B형 간염 예방 또는 치료용 조성물 |
| WO2019240504A1 (en) * | 2018-06-12 | 2019-12-19 | Am Sciences Co., Ltd. | Modified oligonucleotides for inhibition of target gene expression |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225326A (en) * | 1988-08-31 | 1993-07-06 | Research Development Foundation | One step in situ hybridization assay |
| US5610050A (en) * | 1990-04-20 | 1997-03-11 | The General Hospital Corporation | Methods of preventing viral replication |
| WO1992006693A1 (en) * | 1990-10-22 | 1992-04-30 | Fox Chase Cancer Center | Dna construct for providing rna therapy |
| AU681997B2 (en) * | 1991-09-05 | 1997-09-18 | University Of Connecticut, The | Targeted delivery of poly- or oligonucleotides to cells |
| US5585479A (en) * | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
| WO1995017414A1 (en) * | 1993-12-23 | 1995-06-29 | Apollon, Inc. | Anti-hepatitis b viral oligonucleotides |
| US5728518A (en) * | 1994-01-12 | 1998-03-17 | The Immune Response Corporation | Antiviral poly-and oligonucleotides |
| US5646262A (en) * | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
-
1995
- 1995-06-06 US US08/468,352 patent/US5856459A/en not_active Expired - Lifetime
-
1996
- 1996-05-30 ZA ZA964445A patent/ZA964445B/xx unknown
- 1996-06-04 WO PCT/EP1996/002432 patent/WO1996039502A1/en not_active Ceased
- 1996-06-04 CA CA002226458A patent/CA2226458A1/en not_active Abandoned
- 1996-06-04 DE DE69626393T patent/DE69626393T2/de not_active Expired - Lifetime
- 1996-06-04 ES ES96918671T patent/ES2188760T3/es not_active Expired - Lifetime
- 1996-06-04 AU AU61252/96A patent/AU6125296A/en not_active Abandoned
- 1996-06-04 AT AT96918671T patent/ATE233318T1/de not_active IP Right Cessation
- 1996-06-04 EP EP96918671A patent/EP0832211B1/de not_active Expired - Lifetime
- 1996-06-04 DK DK96918671T patent/DK0832211T3/da active
-
1997
- 1997-07-28 US US08/901,612 patent/US6984729B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO1996039502A1 (en) | 1996-12-12 |
| US5856459A (en) | 1999-01-05 |
| US6984729B1 (en) | 2006-01-10 |
| ES2188760T3 (es) | 2003-07-01 |
| AU6125296A (en) | 1996-12-24 |
| DE69626393T2 (de) | 2003-12-04 |
| ZA964445B (en) | 1996-12-06 |
| ATE233318T1 (de) | 2003-03-15 |
| DK0832211T3 (da) | 2003-05-26 |
| CA2226458A1 (en) | 1996-12-12 |
| EP0832211A1 (de) | 1998-04-01 |
| EP0832211B1 (de) | 2003-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE233318T1 (de) | Spezifische oligonukleotide für hepatitis b virus | |
| DE69403642D1 (de) | 7-deazapurin modifizierte oligonukleotide | |
| ATE289519T1 (de) | Zusammensetzungen und verfahren zur behandlung von hepatitis c virus-bedingten erkrankungen | |
| NO965378D0 (no) | Pyrazolo- og pyrolopyridiner | |
| DE69330372D1 (de) | ZUSAMMENSETZUNGEN UND VERFAHREN FüR DIE BEHANDLUNG VON MIT HEPATITIS C VIREN ASSOZIIERTEN KRANKHEITEN | |
| DE69940371D1 (de) | Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline | |
| NO20030845D0 (no) | Utvalgte fusjonerte pyrrolokarbazoler | |
| DE69803391D1 (de) | Zusammensetzung die mindestens ein doppel strangiges rna und mindestens ein interferon enthält, zur behandlung von virale hepatitis | |
| NO983716D0 (no) | Metoksyetoksy oligonukleotider for modulering av protein-kinase C ekspresjon | |
| DE60137631D1 (de) | Ireovirus antikörpern zur behandlung von ras-vermittelten, proliferativen erkrankungen | |
| ATE298741T1 (de) | Polyaromatische verbindungen zur behandlung von herpes-infektionen | |
| EP0755440A4 (de) | Mutierte viren, anti-virale verbindungen und methoden zur herstellung von impfstoffen | |
| DK1123414T3 (da) | Antisense-modulering af integrin alpha 4.ekspression | |
| EP1131107A4 (de) | Antisense-modulation der expression von inhibitor-kappa-b-kinase-alpha | |
| DE60015568D1 (de) | Zusammensetzungen zur behandlung von viralen infektionen und verfahren dafür | |
| ES2091928T3 (es) | Metodos de prevencion de la replicacion virica. | |
| ATE369429T1 (de) | Strukturproteine des virus, welches die pankreas- krankheit bei fischen verursacht, und ihre verwendungen | |
| EP1331267A3 (de) | Spezifische Oligonukleotide für Hepatitis C-Virus | |
| DE69739346D1 (de) | Gereinigtes sr-p70 protein | |
| WO1996039501A3 (en) | Oligonucleotides specific for human papillomavirus | |
| DE69922364D1 (de) | Verfahren zur immunisierung und behandlung von h. pylori infektion | |
| FR2679235B1 (fr) | Methode de purification des aminoacides, des acides nucleiques et de leurs derives. | |
| EA199700438A1 (ru) | Межгенные участки вируса верхушки банановой грозди | |
| ATE493408T1 (de) | Antiinfektiöse mittel | |
| HU9300349D0 (en) | Method for producing dibenzo- or benzo-pyrido-cyclohepta-piperidine derivatives or piperidylidene or piperazine derivatives thereof as well as pharmaceutical preparatives contqining them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |